Investing Profile

Mark Angelino

InvestorVC
Venture Partner at Third Rock Ventures
Photo of Mark Angelino, Venture Partner at Third Rock Ventures

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Hotmail Network
4901 CONNECTIONS
Third Rock Ventures Network
32 CONNECTIONS
Takeda Oncology Network
13 CONNECTIONS
cb
Third Rock Ventures Venture Partner
$100K - $5.0M
$1.5M
$770M
Associate Director, Process Development Takeda OncologyPresent
Senior Director, Process Development and Manufacturing Momenta PharmaceuticalsPresent
Sr. Director, Research and Development; Site Head-Cambridge HotmailPresent
SVP, Pharmaceutical Sciences Bluebird BioPresent
Independent Board Member Arbor BiotechnologiesPresent
Innovation and Technology Advisory group (ITAG) CCRMPresent
Stealth Company (Mark D. A.)Present
Soufflé TherapeuticsPresent
Chief Strategy and Operating Officer Soufflé TherapeuticsPresent
Chief Operating Officer and founder Generation BioPresent
Venture Partner Third Rock VenturesPresent